#Achillion Pharmaceuticals

The Phase IIb trial investigated the safety and efficacy of the JNJ-4178 regimen, which includes odalasvir, AL-335 and Olysio.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.

Achillion has released new data showing excellent results from six weeks of treatment with company’s odalasvir and Gilead’s sofosbuvir.

ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...

The FDA has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625